"The major contribution of EVLP will not be for the large transplant centers like Duke or Toronto, which already use 40% of the organs and for whom a marginal increase is not that large," Dr. Cypel said. "Look at the majority of lung transplant centers that use 10% or less of the offered lungs; that is where we can have a major impact by increasing the number of organs available."
Vitrolife supported the clinical trial. Dr. Cypel and Dr. Keshavjee reported no other relevant disclosures. Dr. Davis said he received research support from Vitrolife for a U.S. study.